Sabra Healthcare SBRA Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Net margin | 19.2%-0.3pp | 20.1%+2.1pp | 23.5%+9.3pp | 24.9%+17.0pp | 19.5%+12.0pp | |
| Returns | ||||||
| Return on equity | 5.7%+0.5pp | 5.6%+1.0pp | 6.3%+2.8pp | 6.7%+4.8pp | 5.1%+3.4pp | |
| Return on invested capital | 9.8%— | 9.6%— | 10.7%— | —— | —— | |
| Efficiency | ||||||
| Asset turnover | 0.2×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×— | 0×— | |
| Net debt / EBITDA | -0.2×-0.2× | -0.1×0.0× | -0.4×-0.3× | -0.2×— | -0×— | |
| Per Share | ||||||
| Book value per share | $10.88-3.2% | $11.54-0.6% | $11.60+0.2% | $11.25-4.8% | $11.25-5.2% | |
| Valuation | ||||||
| Market capitalization | $4.85B+16.7% | $4.72B+15.3% | $4.47B+3.7% | $4.41B+23.7% | $4.16B+21.7% | |
| Price / earnings | 31×+1.5× | 30.3×-2.0× | 25.5×-18.8× | 24.2×— | 29.5×— | |
| Price / sales | 6×+0.2× | 6.1×+0.3× | 6×-0.3× | 6×+0.7× | 5.8×+0.5× | |
| Price / book | 1.7×+0.2× | 1.7×+0.2× | 1.6×0.0× | 1.6×+0.3× | 1.5×+0.3× | |
| EV / EBITDA | 10.2×+0.5× | 10.3×+0.5× | 9.2×-1.5× | 9.3×— | 9.7×— | |
| Dividend yield | 6.1%-0.7pp | 6.1%-0.7pp | 6.4%-0.1pp | 6.4%-1.3pp | 6.8%-1.3pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Sabra Healthcare's ratios come from?
- Every ratio is computed from Sabra Healthcare's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
